<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fosdenopterin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fosdenopterin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fosdenopterin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="130899" href="/d/html/130899.html" rel="external">see "Fosdenopterin: Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="131003" href="/d/html/131003.html" rel="external">see "Fosdenopterin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55567192"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nulibry</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F55561218"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Molybdenum Cofactor;</li>
<li>
                        Substrate Replacement Therapy</li></ul></div>
<div class="block doa drugH1Div" id="F55682036"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4779f2d4-996f-4abe-be1c-7ae07313dcd3">Molybdenum cofactor deficiency type A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Molybdenum cofactor deficiency type A: IV:</b> 0.9 mg/kg once daily (using actual body weight).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> If a dose is missed, administer the missed dose as soon as possible; the next scheduled dose should be administered at least 6 hours after the missed dose.</p></div>
<div class="block dora drugH1Div" id="F55682038"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F55682039"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F55682037"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F55668522"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="130899" href="/d/html/130899.html" rel="external">see "Fosdenopterin: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4779f2d4-996f-4abe-be1c-7ae07313dcd3">Molybdenum cofactor deficiency type A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Molybdenum cofactor deficiency (MoCD) type A: Note: </b>Initiate therapy with confirmed or presumptive diagnosis of MoCD type A. Confirm presumptive diagnosis as soon as possible; discontinue treatment if genetic testing does not confirm diagnosis.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: IV: Initial: 0.55 mg/kg/dose once daily for 1 month, then increase to 0.75 mg/kg/dose once daily for 2 months, then increase to target dose of 0.9 mg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV: 0.9 mg/kg/dose once daily.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F55668523"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F55668524"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F56124934"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Photosensitivity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Animal studies suggest that use of fosdenopterin may result in sensitivity to sunlight and UVA or UVB phototherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unknown</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">â€¢ Exposure to direct sunlight or artificial UV light without the use of precautionary measures (eg, use of protective clothing and hats, broad spectrum sunscreen with a high protection factor [SPF], sunglasses).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55560999"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Maculopapular rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, gastroenteritis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Bacteremia, influenza, viral infection</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Catheter complication (catheter site complications)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Swelling of eye</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis media</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, lower respiratory tract infection, oropharyngeal pain, pneumonia, sneezing, tonsillitis (viral), viral upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F55555279"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F55682025"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Photosensitivity: May increase sensitivity to sunlight; avoid or minimize exposure to direct sunlight and artificial UV light exposure (including UVA or UVB phototherapy), and utilize precautionary measures (eg, protective clothing, hat, sunglasses); use a broad spectrum sunscreen with high sun protection factor in patients â‰¥6 months. If photosensitivity occurs, patients should seek medical attention immediately with consideration of dermatological evaluation.</p></div>
<div class="block foc drugH1Div" id="F55567193"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as hydrobromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nulibry: 9.5 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as hydrobromide [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nulibry: 9.5 mg (1 ea [DSC]) [latex free]</p></div>
<div class="block geq drugH1Div" id="F55567191"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F55670734"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Nulibry Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">9.5 mg (per each): $1,785.60</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F55682040"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> If reconstituted vial has been refrigerated, allow to come to room temperature (by hand warming for 3 to 5 minutes or exposing to ambient air for ~30 minutes) before administration; do not heat. Administer by IV infusion at 1.5 mL/minute through a 0.2 micron filter with nonâ€“di-2-ethylhexyl phthalate (DEHP) tubing; complete infusion within 4 hours after reconstitution. Do not mix or administer with other medications. May be administered by caregiver/patient if deemed appropriate following necessary training and instruction.</p></div>
<div class="block admp drugH1Div" id="F55668526"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: If reconstituted solution is refrigerated following preparation, allow solution to come to room temperature prior to administration. Do not heat; do not refreeze. Administer with non-DEHP tubing through a 0.2 micron filter via infusion pump at a rate of 1.5 mL/minute. Dose volumes &lt;2 mL may require slow IV push via syringe. Administration must be completed within 4 hours of preparation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> If a dose is missed, administer the dose as soon as possible and then administer next dose â‰¥6 hours after administration of missed dose.</p></div>
<div class="block use drugH1Div" id="F55555278"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Molybdenum cofactor deficiency type A:</b> To reduce the risk of mortality in patients with molybdenum cofactor deficiency type A.</p></div>
<div class="block cyt drugH1Div" id="F55609802"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F55609799"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F55682023"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted.</p></div>
<div class="block brc drugH1Div" id="F55682024"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if fosdenopterin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block pha drugH1Div" id="F55682029"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fosdenopterin is a cyclic pyranopterin monophosphate that undergoes conversion to molybdopterin, which is further converted to molybdenum cofactor. Molybdenum cofactor is required for molybdenum-dependent enzyme activation, including sulfite oxidase, which reduces levels of neurotoxic sulfites (eg, S-sulfocysteine).</p></div>
<div class="block phk drugH1Div" id="F55682030"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Pharmacokinetic data is based on a single infusion administered to healthy adult subjects.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~300 mL/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 6% to 12%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily via nonenzymatic degradation processes to compound Z, an inactive oxidation product of endogenous cyclic pyranopterin monophosphate.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 1.2 to 1.7 hours.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Nulibry.1">
<a name="Nulibry.1"></a>Nulibry (fosdenopterin) [prescribing information]. Charleston, SC: Alcami Carolinas Corporation; October 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 130898 Version 36.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
